Roschier represented KKR’s life science platform Gamma in the sale of Astrea to Biotage
Global investment firm KKR’s life science platform Gamma Biosciences has sold Astrea Bioseparations to Biotage for a purchase price of USD 215 million. Roschier advised KKR and Gamma Biosciences with respect to Swedish law and Gibson Dunn & Crutcher advised KKR and Gamma with respect to UK law.
The purchase price of USD 215 million will be paid in the form of shares in Biotage, which are to be issued at the coming annual general meeting and up to an additional USD 45 million in mile-stone based cash payments following the completion of the transaction.
After the transaction, Gamma Biosciences will become the largest shareholder in Biotage with a shareholding of approximately 17 per cent. The transaction is subject to customary closing conditions.